Search
aprotinin (Kunitz pancreatic trypsin inhibitor, kallikrein-trypsin inactivator)
Pharmacology: see Trasylol. (voluntary marketing suspension, 2007)
Specific
Trasylol (aprotinin)
General
hematologic agent
Kunitz type serine protease inhibitor
trypsin inhibitor
Properties
INHIBITS: trypsin
MOTIF: Kunitz-type serine protease inhibitor [KPI] domain
MOTIF: cysteine residue {X+0}
MODIFICATION: cysteine residue {X+X5}
cysteine residue {X+X1}
MODIFICATION: cysteine residue {X+X3}
cysteine residue {X+X2}
MODIFICATION: cysteine residue {X+X4}
cysteine residue {X+X3}
MODIFICATION: cysteine residue {X+X1}
cysteine residue {X+X4}
MODIFICATION: cysteine residue {X+X2}
cysteine residue {X+X5}
MODIFICATION: cysteine residue {X+0}
FOR-BINDING-OF: serine protease
References
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- FDA Medwatch
http://www.fda.gov/medwatch/safety/2006/safety06.htm#Trasylol
http://www.fda.gov/medwatch/safety/2007/safety07.htm#Aprotinin
- Mangano DT et el,
The risk associated with aprotinin in cardiac surgery
N Engl J Med 354:353, 2006
PMID: 16436767